Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess Safety and Effect of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05110703
Recruitment Status : Completed
First Posted : November 8, 2021
Last Update Posted : July 11, 2022
Sponsor:
Information provided by (Responsible Party):
Uplifting Results Labs Inc.

Brief Summary:
This study is a double-blind, randomized, trial of a commercially available meal-replacement shake versus a placebo control designed to evaluate the impact on quality of life, safety, and tolerability. It also includes a randomized, non-blinded third arm consisting of only dietary guidelines.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Dietary Supplement: Supergut Dietary Supplement: Placebo Other: Dietary guidelines Not Applicable

Detailed Description:

A total of 147 participants will be recruited for the study following screening, with the expectation that approximately 131 participants will complete the trial. The 147 participants will be randomized to the three different study arms in a 2:1:1 ratio with the commercially available meal-replacement shake group being the one favored, i.e., 73 participants in that arm and 37 in the other two arms.

The trial will be mostly virtual, with in-person visits to a laboratory facility for blood draws, as well as standardized BMI calculations, waist circumference, and blood pressure readings. A technology platform will be utilized to screen, enroll and capture study data of the participants.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 192 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This will be a 3-arm randomized, double-blinded (for the two meal replacement arms), placebo-controlled study
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Effect on Quality of Life of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes
Actual Study Start Date : October 11, 2021
Actual Primary Completion Date : March 1, 2022
Actual Study Completion Date : March 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Fiber

Arm Intervention/treatment
Active Comparator: Dietary supplement: Prebiotic fiber meal replacement shake
Prebiotic fiber meal replacement shake
Dietary Supplement: Supergut
Meal replacement shake

Placebo Comparator: Dietary supplement: Placebo meal replacement shake
Placebo meal replacement shake
Dietary Supplement: Placebo
Placebo

Dietary guidelines
Dietary guidelines
Other: Dietary guidelines
Dietary guidelines




Primary Outcome Measures :
  1. Examination of the effect of daily use of a prebiotic fiber meal replacement (PFMR) shake on quality of life [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    The endpoint will be reported by the participant on a scale to measure the quality of life. Participants will complete the surveys at baseline and 12-weeks. The study uses a questionnaire including a scale from 0-5 to assess their quality of life(0=not a problem and 5=a very serious problem).


Secondary Outcome Measures :
  1. To examine the effect of PFMR shakes on hunger [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    The endpoints will be reported by the participant as follows: Hunger: surveys at baseline and 12-weeks. The study uses a questionnaire including a scale from 0-10 to assess hunger (0=starving & beyond and 10=thanksgiving full)

  2. Changes from baseline on gastrointestinal symptoms after daily use of PFMR shakes [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    The endpoints will be reported by the participant as follows: Gastrointestinal symptoms: surveys at baseline and 12-weeks. The study uses a questionnaire including a scale from 0-7 to assess gastrointestinal discomfort (0=no discomfort at all and 7=very severe discomfort)

  3. Changes from baseline in fruit, vegetable, and fiber consumption. [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    The endpoints will be reported by the participant as follows: Fruit, vegetable, and fiber consumption: surveys at baseline and 12-weeks. The study uses a questionnaire including a scale from 0-6 to assess consumption (0=no consumption; 6=daily consumption)

  4. Changes from baseline in A1C associated with type 2 diabetes (T2D) after daily use of PFMR shakes [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    Changes in biomarkers associated with T2D (changes in a1c) at baseline, 4-weeks, and 12-weeks.

  5. Changes from baseline in blood pressure after daily use of PFMR shakes on blood pressure. [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    Changes in blood pressure at baseline, 4-weeks, and 12-weeks.

  6. Changes from baseline in body weight after daily use of PFMR shakes. [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    Changes in body weight (in lbs) are measured at baseline, 4-weeks, and 12-weeks.

  7. Changes from baseline on short-chain fatty acid synthesis from baseline after daily use of PFMR shakes. [Time Frame: Baseline to 12 weeks] [ Time Frame: 12 weeks ]
    Changes is short chain fatty acids synthesis measured with an at-home stool kit at baseline, 4 weeks, and 12 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with T2D for ≥90 days
  • HbA1c of 7.5 to 10.5%, inclusive
  • BMI of 27 to 50 kg/m2, inclusive
  • Treatment for T2D with lifestyle intervention only (for at least 90 days) or, if using antidiabetic medication(s), treated with a stable daily dose (for at least 90 days) of any of the following agents alone or in any combination: metformin (any formulation), sulfonylurea (e.g., glyburide, glipizide, glimepiride), DPP-4 inhibitor (e.g., sitagliptin, saxagliptin, linagliptin), SGLT-2 inhibitor (e.g., empagliflozin, canagliflozin, dapagliflozin, ertugliflozin), GLP-1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide)

Exclusion Criteria:

  • Have type 1 diabetes or secondary forms of diabetes (e.g., secondary to cystic fibrosis)
  • Have a history of severe hypoglycemia or hyperglycemia requiring hospitalization within the prior 6 months
  • Have required insulin therapy for the treatment of T2D (with the exception of prior acute, temporary use during a hospitalization and/or for past treatment of gestational diabetes)
  • Treatment with any glucose-lowering agent(s) other than those stated in the inclusion criteria during a period of 90 days prior to screening
  • Receiving chronic oral steroid therapy (excluding those for skin, eyes, nose, or inhaled) or have received such therapy within 1 month of screening
  • Female who is pregnant, breastfeeding or intends to become pregnant during the course of the study
  • Participation in a clinical research trial within 30 days prior to screening
  • Food allergies to ingredients in the shake including but not limited to milk protein allergy
  • Ankylosing spondylitis
  • Crohn's disease
  • Celiac disease
  • Cardiovascular (CV) conditions within 2 months prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization due to congestive heart failure (CHF)
  • Other gastrointestinal conditions which in the investigator's opinion may jeopardize the individual's safety or interfere with the ability to comply with the study.
  • Gastrointestinal surgeries such as those for weight loss, large bowel resection or small bowel resection which in the investigator's opinion may jeopardize the individual's safety or interfere with the ability to comply with the study.
  • Have a history of any other condition such as known drug, alcohol abuse, or psychiatric disorder which in the investigator's opinion may jeopardize the individual's safety or interfere with the ability to comply with the study.
  • Any disorder, unwillingness or inability, which in the investigator's opinion, might jeopardize the individual's safety or interfere with the ability to comply with the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05110703


Locations
Layout table for location information
United States, California
Citruslabs
Santa Monica, California, United States, 90404
Sponsors and Collaborators
Uplifting Results Labs Inc.
Investigators
Layout table for investigator information
Principal Investigator: Juan Frias, MD Uplifting Results Labs Inc.
Layout table for additonal information
Responsible Party: Uplifting Results Labs Inc.
ClinicalTrials.gov Identifier: NCT05110703    
Other Study ID Numbers: 001-001
First Posted: November 8, 2021    Key Record Dates
Last Update Posted: July 11, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Uplifting Results Labs Inc.:
Diabetes
Microbiome
Fiber
Prebiotic
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases